Hybrid imaging plays a central role in the diagnosis and management of a wide range of malignancies at all stages. In this article, we review the most pertinent historical developments, emerging clinical applications of novel radiotracers and imaging technologies, and potential implications for training and practice. This includes an overview of novel tracers for prostate, breast, and neuroendocrine tumors, assessment of tumor heterogeneity, the concept of image-guided 'biologically relevant dosing', and theranostic applications. Recent technological advancements, including time-of-flight PET, PET/MRI, and 'one-minute whole-body PET', are also covered. Finally, we discuss how these rapidly evolving applications might affect current training curricula and how imaging-derived big data could be harnessed to the benefit of our patients.
Keywords: 11C–choline; 18F –Fluciclovine; 18F–Fluorodehydrotestosterone; 18F–Fluoroestradiol; 68Ga/ 177Lu -DOTA-TATE; 89Zr-trastuzumab; Oncologic hybrid molecular imaging; One-minute whole-body PET explorer; Prostate-specific membrane antigen; Time-of-flight positron emission tomography computed tomography.